First Bancorp Inc ME Grows Stock Position in Johnson & Johnson $JNJ

First Bancorp Inc ME lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 8,734 shares of the company’s stock after acquiring an additional 395 shares during the period. First Bancorp Inc ME’s holdings in Johnson & Johnson were worth $1,334,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wealthstream Advisors Inc. boosted its stake in Johnson & Johnson by 3.4% in the 2nd quarter. Wealthstream Advisors Inc. now owns 2,101 shares of the company’s stock worth $321,000 after purchasing an additional 70 shares in the last quarter. SAM Advisors LLC raised its holdings in shares of Johnson & Johnson by 3.0% in the second quarter. SAM Advisors LLC now owns 12,172 shares of the company’s stock worth $1,859,000 after buying an additional 359 shares during the last quarter. Gladwyn Financial Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter worth $71,000. Schubert & Co grew its holdings in shares of Johnson & Johnson by 5.8% during the second quarter. Schubert & Co now owns 2,144 shares of the company’s stock valued at $328,000 after buying an additional 117 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $157,608,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on JNJ. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Bank of America upped their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $199.88.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.6%

Shares of JNJ stock opened at $193.27 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.40. The stock has a market cap of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. The stock has a 50 day moving average of $180.49 and a 200 day moving average of $164.90. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.